Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

04.03.2025

UC loses patent battle over prostate cancer drug in SA

The University of California's (UC) patent for Xtandi, a prostate cancer drug, was revoked in South Africa, allowing generic alternatives to enter the market.

This article is for Health Matters subscribers

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

SubscribeLog in

More from Health Matters

08.11.2026

Xtandi Patent Dispute Heads to Constitutional Court

The Xtandi patent dispute reaches South Africa’s Constitutional Court on 23 November. Read what is at stake for generic access and damages claims.

06.11.2026

Pharmaceutical Sovereignty Put to the Test by Ebola

Pharmaceutical sovereignty is back in focus as Ebola spreads in the DRC. See how pooled procurement and shared regulation could secure supplies.

05.11.2026

Rare Disease Funding in Focus After KeyHealth Ruling

Rare disease funding is under scrutiny after the KeyHealth ruling. See how schemes could share the cost of treatments such as Ultomiris.